Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic, Cardiovascular, and Immunological Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HDAC9 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HDAC9 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for binding assays and selectivity profiling. |
View HDAC9 Products |
| Gene Delivery | HDAC9 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View HDAC9 Products |
| Benchmark Ab | Anti-HDAC9 Recombinant Antibody High-affinity positive control for Western Blot, IHC, and IP validation. |
View HDAC9 Products |
| Validator | HDAC9 siRNA Set Target-specific knockdown verification in cellular assays. |
View HDAC9 Products |
| Related Target A | HDAC4 Class IIa subfamily member. Essential for off-target selectivity screening panels. |
View HDAC4 Products |
| Related Target B | HDAC5 Class IIa subfamily member. Shared structural homology; critical for cross-reactivity profiling. |
View HDAC5 Products |
| Related Target C | MEF2C Transcription factor partner. HDAC9 acts as a transcriptional corepressor by binding to MEF2C. |
View MEF2C Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Class IIa Subfamily Selectivity Screening | Full panel of Class IIa recombinant proteins (HDAC4, HDAC5, HDAC7, HDAC9) strictly verified by mass spectrometry and sequence analysis. |
| Off-Target Toxicity Profiling (Class I HDACs) | High-purity Class I HDAC counter-screening targets (HDAC1, HDAC2, HDAC3, HDAC8) available to ensure compound selectivity. |
| Lack of Validated Controls | Sequence-verified clinical benchmark antibodies and positive control reagents included in the portfolio. |
| False Positive Knockdown Data | Sequence-optimized siRNA pools designed for robust target knockdown with minimal off-target effects. |
Live HDAC9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Histone Deacetylase 9 (HDAC9) is rapidly expanding beyond oncology into cardiovascular, metabolic, and autoimmune diseases. As a Class IIa HDAC, HDAC9 exhibits unique tissue distribution and functions primarily as a transcriptional co-repressor. Unlike Class I HDACs, which possess robust enzymatic activity, HDAC9 regulates gene expression through protein-protein interactions (e.g., with MEF2) and chromatin remodeling complexes.
The race for HDAC9 therapeutics is intensifying, with major players shifting focus from traditional pan-HDAC inhibitors to highly selective Class IIa inhibitors and targeted protein degraders (PROTACs). As first-generation therapies reach the clinic, the next wave of R&D is targeting isoform-selective pocket binding and tissue-specific delivery to minimize systemic toxicities associated with broad HDAC inhibition.
Competitive Modality & Indication Snapshot
Connecting market trends to precise assay development needs:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecules | Pharmaceutical & Academic Consortia | Atherosclerosis, Stroke, Autoimmune Diseases | Selectivity Assay (Requires high-purity HDAC9 vs. HDAC1/2/3/4/5 proteins) |
| PROTACs / Degraders | Biotech Startups, Targeted Protein Degradation Pioneers | Oncology (Medulloblastoma, T-ALL), Fibrosis | Ternary Complex Formation (Requires tag-optimized recombinant HDAC9 and target-specific antibodies) |
| Gene Therapy / RNAi | RNA Therapeutics Specialists | Vascular Calcification, Cardiomyopathy | In vitro validation (Requires sequence-verified siRNA and stable cell lines via Lentivirus) |